Vvm Biotech Infra Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 04-07-2024
- Paid Up Capital ₹ 1.00 M
as on 04-07-2024
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.50 M
as on 04-07-2024
- Revenue -28.79%
(FY 2023)
- Profit -10.85%
(FY 2023)
- Ebitda -2.35%
(FY 2023)
- Net Worth 26.45%
(FY 2023)
- Total Assets -34.40%
(FY 2023)
About Vvm Biotech Infra
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹3.50 M.
Arvind Mishra, Ruchi Mishra, and Javed Mohammad serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC285666
- Company No.
285666
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Sep 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Ambernath, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
- Apps
What products or services does Vvm Biotech Infra Private Limited offer?
Vvm Biotech Infra Private Limited offers a wide range of products and services, including Eye Diagnosis & Surgery Instruments, Eye Testing Machines, Hospital and Medical Furniture, Medical Trolley, Diagnostic Medical Imaging Equipment, Doppler Machine, Medical Laboratory Instruments, Corona Test Kit, Computer Hardware & Peripherals, Monitor Accessories.
Who are the key members and board of directors at Vvm Biotech Infra?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ruchi Mishra  | Director | 08-Sep-2016 | Current |
| Javed Mohammad | Director | 27-Nov-2021 | Current |
| Arvind Mishra | Director | 08-Sep-2016 | Current |
Financial Performance and Corporate Structure Insights of Vvm Biotech Infra.
Vvm Biotech Infra Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 28.79% decrease. The company also saw a substantial fall in profitability, with a 10.85% decrease in profit. The company's net worth Soared by an impressive increase of 26.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vvm Biotech Infra?
In 2023, Vvm Biotech Infra had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Dec 2021 | ₹3.50 M | Open |
How Many Employees Work at Vvm Biotech Infra?
Unlock and access historical data on people associated with Vvm Biotech Infra, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vvm Biotech Infra, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vvm Biotech Infra's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
